Medical organizations that can claim to be registered as a company with limited guarantee are a handful only. One of them is National Diabetes Institute or better known as NADI. It is no coincidence that the acronym is NADI, as the company aims to be the pulse of diabetes education and centre of excellence dedicated to diabetes.
Semaglutide has superior efficacy in reducing glucose levels and body weight over a range of comparator treatments, according to findings from the phase 3 SUSTAIN 1–5* trials.
The cardiovascular (CV) efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes (T2D) appear to be a class effect, according to a systematic review and meta-analysis of four major GLP-1 CV safety trials.